Interview with Esther Lim, Managing Partner, Finnegan
Finnegan is a leader and expert on the topic of intellectual property and it entered Asia in the late 1980s with an office in Tokyo yet China only very recently.…
Address: Mirae Asset Tower 28/F, Unit A-B No. 166 Lujiazui Ring Road, Pudong Shanghai, China 200120,China
Tel: 86 21 6194 2000
Web: http://www.finnegan.com/en-US/locations/region.aspx?region=5
Finnegan has more than 40 years of experience in successfully navigating U.S. IP law. Finnegan works with clients of all sizes, from virtually every industry and technology to identify, protect, advocate, and leverage their most valuable IP assets. Finnegan guides U.S. organizations as well as multinational entities that wish to conduct business in the U.S. Foreign innovators entering the U.S. market are often surprised at the intricacies of the intellectual property legal system. Patent law is becoming increasingly complex, with regulatory and legislative changes having a dramatic impact on companies’ intellectual property and business strategies. Finnegan views this complexity as an opportunity to think creatively. Finnegan’s full range of IP experience—from idea protection and management to litigation and appeals—gives the company the perspective to anticipate potential issues and devise creative solutions.
Asia boasts some of the world’s most sophisticated markets and fastest growing economies. Innovative corporations and organizations across Asia turn to Finnegan to identify, protect, advocate, and leverage their most valuable IP assets. To meet the needs of Finnegan’s Asian clients conducting business in their headquarter countries or in the United States, Finnegan has established offices in Shanghai, Taipei, and Tokyo. The firm also has strong ties to the IP legal communities in Korea and India, and our attorneys regularly travel to these countries to speak at conferences and meet with clients.
Finnegan’s licensed Foreign Representative Office in China is located in the Pudong area of Shanghai, and Finnegan’s attorneys are able to serve clients anywhere in the greater China region. As Chinese companies continue to expand their markets, Finnegan is on the ground to assist them with their U.S. IP strategies and needs.
Finnegan is proud to have been active and involved in the Chinese community for many years. We have over 30 professionals who speak Chinese, many with degrees from Chinese universities. Our local outreach efforts have included seminars, educational programs, and roundtable discussions for both business groups and universities. We are particularly active in U.S. IP licensing matters in China.
Intellectual Property Law
Finnegan is a leader and expert on the topic of intellectual property and it entered Asia in the late 1980s with an office in Tokyo yet China only very recently.…
China’s regulator approved a biosimilar version of Roche’s Rituxan this week, the first such drug ever to be given the green light in the country. With numerous other biological copycats…
The lowdown on what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. Robert Hall of Ardent Search outlines…
George Lee, vice-president of clinical operations and country leader of PAREXEL in China, discusses the impact of the recent ownership and management changes of the group, the value that PAREXEL…
One of the earliest innovative biotech companies in China, Zensun has developed what its founder Dr Zhou Mingdong calls a rare made-in-China first-in-class therapeutic candidate, the cardiology treatment, Neucardin®. With…
It has been announced by China’s State Council that as of March 1st 2019, the government will reduce the VAT on a “first batch” of 21 rare disease drugs and four…
This is the first in a series of articles examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging…
Terns Pharmaceuticals is developing innovative drugs for the treatment of NASH and liver disease. It has established a diverse product pipeline with drug candidates targeting different stages of the disease…
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. Together with his colleague Sarah Hassan, a researcher at the company they look at China’s skyrocketing health industry and what to expect from it in the…
Brian Mi, president of IQVIA Greater China, shares IQVIA’s leadership position in China in both the commercial and R&D space, building on both IMS Health and Quintiles’ market positioning in…
Even though China’s pharmaceutical sector remains largely generics-based, the Middle Kingdom’s biotechnology scene has been flourishing in recent years. Now the world’s fastest-growing biopharmaceutical market, China can boast a much-improved…
Dr Xu Ting, founder, chairman and CEO of Alphamab Oncology, shares his expert opinion on the recent regulatory and healthcare reforms in China, the expertise Alphamab Oncology has in protein…
Jack Wang, founder and CEO of Biomobie, shares the inspirational story behind the establishment of the company, the regenerative principle driving the technology of the Bioboostie device, and the innovative…
See our Cookie Privacy Policy Here
